THE RECOMMENDED DOSAGE RANGE IS 25 TO 100 HYLAND FACTOR VIII CORRECTIONAL UNITS PER KG OF BODY WEIGHT, DEPENDING UPON THE SEVERITY OF HEMORRHAGE. IF NO HEMOSTATIC IMPROVEMENT IS OBSERVED APPROXIMATELY 6 HOURS FOLLOWING THE INITIAL ADMINISTRATION, THE DOSAGE SHOULD BE REPEATED.
SUBSEQUENT DOSAGE AND ADMINISTRATION INTERVALS SHOULD BE ADJUSTED ACCORDING TO THE PATIENT'S CLINICAL RESPONSE.
RATE OF ADMINISTRATION:
IT IS RECOMMENDED THAT AUTOPLEX® T, ANTI-INHIBITOR COAGULANT COMPLEX, HEAT TREATED, BE INFUSED INITIALLY AT A RATE OF 2 ML/MIN. IF INFUSION AT THIS RATE IS WELL TOLERATED THE ADMINISTRATION RATE MAY BE GRADUALLY INCREASED TO 10 ML/MIN
PATIENTS WHOSE PRESENT FACTOR VIII INHIBITOR LEVELS ARE GREATER THAN 10 BETHESDA UNITS, AS WELL AS PATIENTS WHOSE INHIBITOR LEVELS ARE HISTORICALLY KNOWN TO RISE TO GREATER THAN 10 BETHESDA UNITS FOLLOWING TREATMENT WITH ANTIHEMOPHILIC FACTOR (HUMAN), SHOULD BE TREATED WITH ANTI-INHIBITOR COAGULANT COMPLEX.
PATIENTS WHOSE PRESENT FACTOR VIII INHIBITOR LEVELS ARE BETWEEN 2 AND 10 BETHESDA UNITS AND WHOSE INHIBITOR LEVELS ARE HISTORICALLY KNOWN TO REMAIN IN THIS RANGE FOLLOWING TREATMENT WITH ANTIHEMOPHILIC FACTOR (HUMAN) MAY BE TREATED WITH EITHER ANTIHEMOPHILIC FACTOR (HUMAN) OR ANTI-INHIBITOR COAGULANT COMPLEX, DEPENDING ON THE PATIENT'S CLINICAL HISTORY AND THE SEVERITY OF THE BLEEDING EPISODE.
PATIENTS WITH FACTOR VIII INHIBITOR LEVELS OF LESS THAN 2 BETHESDA UNITS WHOSE INHIBITOR LEVELS ARE HISTORICALLY KNOWN TO REMAIN AT 2 BETHESDA UNITS OR LESS FOLLOWING TREATMENT WITH ANTIHEMOPHILIC FACTOR (HUMAN) MAY BE TREATED WITH APPROPRIATE DOSES OF ANTIHEMOPHILIC FACTOR (HUMAN).